Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents

Bone-modifying agents (BMAs), with bone-resorptive inhibitory effects, such as zoledronic acid and denosumab, are widely used at higher doses for bone-related events caused by bone metastasis of malignant tumors. These drugs have been suggested to be associated with atypical femoral fractures (AFFs)...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Tomoaki Fukui, Keisuke Oe, Teruya Kawamoto, Masayuki Morishita, Ikuo Fujita, Shunsuke Takahara, Atsushi Sakurai, Takashi Iwakura, Keiji Yoshida, Kenjiro Ito, Etsuo Shoda, Takafumi Hiranaka, Masaya Tsunoda, Ryosuke Kuroda, Takahiro Niikura
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2023-06-01
Σειρά:	Journal of Bone Oncology
Θέματα:	Atypical femoral fracture Bone metastasis Zoledronic acid Denosumab Bone-modifying agent Bisphosphonate
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2212137423000118
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!